文献速递银屑病与炎症性皮肤病

知名活性成分的再制剂可改善寻常型银屑病外用治疗的临床结局

Reformulations of well-known active ingredients in the topical treatment of psoriasis vulgaris can improve clinical outcomes for patients.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2017-05-22

本文为文献综述,检索2001–2016年Embase和PubMed中比较同一活性成分不同制剂的头对头研究,共纳入22篇出版物(19项头对头临床试验、1项汇总分析、1项健康经济模型研究、1项系统综述)。结果显示,丙酸氯倍他索、卡泊三醇、倍他米松及卡泊三醇/二丙酸倍他米松复方制剂的再制剂在部分试验中显著改善临床结局和患者报告结局,提示优化载体可提升现有活性成分的疗效。

要点

  • 再制剂可显著改善部分外用活性成分的临床结局和患者报告结局。
  • 丙酸氯倍他索、卡泊三醇、倍他米松及Cal/BD复方制剂有再制剂获益证据。
  • 改善外用治疗不仅依赖新靶点,优化载体同样可带来临床获益。

核心结论

  • 对寻常型银屑病常用外用活性成分进行创新再制剂,可在部分试验中显著改善临床结局和患者报告结局。
  • 改善外用治疗不仅可通过发现新靶点和新活性成分实现,优化现有活性成分的载体也可能带来显著临床和患者获益。

研究设计与样本

  • 文献综述,检索Embase和PubMed中2001–2016年发表的、对同一活性药物成分不同制剂进行直接头对头比较的文章,关注临床结局和患者报告结局。
  • 共纳入22篇关于活性成分或活性成分组合的出版物,包括19项头对头临床试验、1项汇总分析、1项健康经济模型研究和1项系统综述。

主要发现

  • 与旧制剂相比,再制剂显示显著临床获益:丙酸氯倍他索3项试验、卡泊三醇1项试验、倍他米松3项试验、卡泊三醇/卡泊三烯+二丙酸倍他米松复方制剂5项试验/汇总分析。
  • 与旧制剂相比,再制剂显示显著患者报告结局改善:丙酸氯倍他索3项试验、戊酸倍他米松1项试验、卡泊三醇/卡泊三烯+二丙酸倍他米松复方制剂2项试验。

临床怎么用

  • 临床选择外用制剂时,除活性成分外应关注制剂工艺和载体优化对疗效及患者报告结局的潜在影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Although the majority of patients with psoriasis vulgaris are treated exclusively with topical therapies, research to develop more effective topical therapies that are associated with higher patient satisfaction has lagged behind the development of systemic agents. The aim of this literature review was to determine whether there is documented evidence that applying an innovative approach to improving the formulation of active ingredients commonly used in the topical treatment of psoriasis can have a positive effect on clinical outcomes and patient-reported outcomes (PROs). The Embase and PubMed databases were searched for articles published between 2001 and 2016 that made direct head-to-head comparisons of different formulations of an active pharmaceutical ingredient (API), focusing on clinical outcomes and PROs. In total, 22 publications on APIs or API combinations met the eligibility criteria (19 head-to-head clinical trials, one pooled analysis, one health-economic modelling study and one systematic review). Significant clinical benefit associated with the use of a reformulated API over an older formulation was reported in three trials of clobetasol propionate, one trial of calcipotriol, three trials of betamethasone and five trials/pooled analyses of calcipotriol/calcipotriene + betamethasone dipropionate (Cal/BD) formulations. Significantly improved PROs associated with the use of a reformulated API over an older formulation were reported in three trials of clobetasol propionate, one trial of betamethasone valerate and two trials of Cal/BD formulations. These results demonstrate that the innovative reformulation of APIs used in the treatment of psoriasis can produce therapies that attain significantly improved clinical outcomes and PROs. This suggests that improvement in topical therapy for psoriasis need not only to be achieved by the identification of new targets and the development of new APIs, but that improvement in the vehicle used to deliver existing APIs has the potential to result in significant clinical and patient benefits.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Iversen L, Dauden E, Segaert S, et al. Reformulations of well-known active ingredients in the topical treatment of psoriasis vulgaris can improve clinical outcomes for patients. J Eur Acad Dermatol Venereol. 2017. PMID: 28419600. doi:10.1111/jdv.14277

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。